Amgen names Howard Chang head of research and CSO
Plus: Head of R&D Blackman retires from Day One, and updates from Karyopharm and L.E.K.
Amgen Inc. (NASDAQ:AMGN) hired Howard Chang as SVP of research and CSO, effective Dec. 16. Chang, who succeeds Ray Deshaies, is a professor at Stanford University and won the 2024 Lurie Prize for his work uncovering the existence of long-non coding RNAs, part of the 98% of the human genome that doesn’t encode proteins, and their roles in disease. Biotechs co-founded by Chang include Accent Therapeutics Inc., Boundless Bio Inc. (NASDAQ:BOLD), Cartography Biosciences Inc. and Orbital Therapeutics Inc.
Head of R&D Samuel Blackman will retire from Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) at year-end. CMO Elly Barry will lead the cancer company’s clinical and medical teams while it searches for a successor. Blackman co-founded Day One and will continue as strategic adviser and consultant...